This week, our featured physician executive is Krishna R. Polu, M.D.
Earlier this month, Affymax, Inc. (NASDAQ:AFFY) announced the promotion of Krishna Polu, M.D. to vice president, Clinical Development. Dr. Polu, a nephrologist, joined Affymax in 2009 as executive director, Clinical Development.
Prior to joining Affymax, Dr. Polu was executive director, Global Development at Amgen where he was responsible for clinical programs in nephrology, diabetes and heart failure. Specifically, he led the global clinical development programs for both EPOGEN and Aranesp while at Amgen. Before joining Amgen, he was a clinical and research fellow at Harvard Medical School in the Renal Division at Brigham and Women’s Hospital and Massachusetts General Hospital. He earned a B.A. in Human Biology from Stanford University and a M.D. from University of Texas Health Science Center, San Antonio. He completed his residency training in Internal Medicine at the University of Colorado.